The FDA has approved Casgevy, the first CRISPR therapy for sickle cell disease, marking a significant milestone in gene editing. Casgevy is a one-time gene editing cell therapy designed to treat patients with sickle cell disease, often referred to as the 'first molecular disease.' The therapy, however, comes with a challenging clinical process and a $2.2 million price tag. MaxCyte played a crucial role in this breakthrough, utilizing its electroporation technology to successfully edit the genes of Victoria Gray and numerous other patients. This approval highlights the potential of gene editing technology in revolutionizing disease treatment.
Gene editing technology is revolutionizing disease treatment | The Excerpt https://t.co/G9xXj46LeG
CRISPR Editing Strategy May Eliminate Toxic Conditioning for Cell Therapy Inserting a natural human variant enhances red blood cell production without disrupting hematopoietic stem and progenitor cell functionality. Learn more: https://t.co/6bVpCIc1IH https://t.co/rAvXtnOsqw
this week in bio: • "Bust to Boom" in biotech • gene editing in the lungs • advancements in colonic organoids • increasing access to pediatric CGT https://t.co/HqMfn79lTx https://t.co/M2BiVc2xxv
On the Charge: MaxCyte Celebrates Role in Sickle Cell Therapy Breakthrough MaxCyte's electroporation prowess played a critical part in the successful gene editing of Victoria Gray’s cells and dozens of other sickle cell disease patients. Learn more: https://t.co/LTpNM6pZq6 https://t.co/GtTMmHinMO
FDA Approves the First CRISPR Therapy for Sickle Cell Disease Casgevy, a one-and-done gene editing cell therapy for patients with the "first molecular disease,” is a triumph but comes with an arduous clinical process and $2.2 million price tag: https://t.co/uVQxQv1odq